HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB‐3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY. (June 2017) - Seymour, J.F.; Opat, S.; Cull, G.; Trotman, J.; Gottlieb, D.; Simpson, D.; Marlton, P.; Anderson, M.; Ku, M.; Ritchie, D.S.; Ratnasingam, S.; Augustson, B.; et al.